Data Sheet

Product Name:	CTX-471
Cat. No.:	CS-0612688
CAS No.:	2377152-49-1
Molecular Formula:	CT
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Solubility:	10 mM in DMSO

CTX-471

BIOLOGICAL ACTIVITY:

CTX-471 is a fully **human monoclonal antibody of CD137**. CTX-471 has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with **K_d** values of 50 nM, 61 nM and 748 nM, respectively. CTX-471 can be used for the research of immunomodulation and cancer[1]. IC50 & Target:Kd for CD137: 50 nM (human); 61 nM (cynomolgus macaque); 748 nM (mouse)[1] ***In Vitro:***CTX-471 (5-500 nM) has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with K_d values of 50 nM, 61 nM and 748 nM, respectively[1].

CTX-471 binds to a unique epitope on CD137[1].

CTX-471 (0.1-100 nM; 1, 10 μg/mL; 3 days) increases IFN-y production by human T cells in an Fcy receptor-dependent (FcyR-dependent) manner in vitro[1]. ***In Vivo:***CTX-471 (i.p.; 150 μg) exhibits curative monotherapy activity in various syngeneic tumor models and shows a unique ability to cure mice of very large tumors. CTX-471 (i.v.; 10-80 mg/kg; on days 0, 7, 14, and 21) is well tolerated, with no signs of hepatic toxicity in high doses.

References:

[1]. Ugur Eskiocak, et al. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity. JCI Insight. 2020 Mar 12;5(5):e133647.

CAIndexNames:

CTX 471

SMILES:

[3H][C][X471]

Tel: 610-426-3128 Fax: 888-484-5008 E-mail: sales@ChemScene.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA